Sterling Capital Management LLC Trims Holdings in MEDNAX Inc (MD)

Sterling Capital Management LLC trimmed its holdings in shares of MEDNAX Inc (NYSE:MD) by 89.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,471 shares of the company’s stock after selling 350,220 shares during the quarter. Sterling Capital Management LLC’s holdings in MEDNAX were worth $1,838,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Cubist Systematic Strategies LLC grew its holdings in MEDNAX by 1,252.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 37,216 shares of the company’s stock worth $1,611,000 after acquiring an additional 34,465 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in MEDNAX during the 2nd quarter worth approximately $172,000. AMP Capital Investors Ltd grew its holdings in MEDNAX by 37.9% during the 2nd quarter. AMP Capital Investors Ltd now owns 32,736 shares of the company’s stock worth $1,417,000 after acquiring an additional 9,000 shares during the last quarter. OppenheimerFunds Inc. grew its holdings in MEDNAX by 24.7% during the 2nd quarter. OppenheimerFunds Inc. now owns 22,296 shares of the company’s stock worth $965,000 after acquiring an additional 4,415 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in MEDNAX by 3.4% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 36,599 shares of the company’s stock worth $1,584,000 after acquiring an additional 1,196 shares during the last quarter. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE MD opened at $47.68 on Friday. The company has a market capitalization of $4.48 billion, a PE ratio of 13.92, a PEG ratio of 1.30 and a beta of 0.24. MEDNAX Inc has a 52-week low of $40.56 and a 52-week high of $63.04. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.52 and a current ratio of 1.52.

MEDNAX (NYSE:MD) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $1.07 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.07. The firm had revenue of $915.90 million for the quarter, compared to the consensus estimate of $911.77 million. MEDNAX had a net margin of 9.59% and a return on equity of 10.42%. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.85 EPS. equities research analysts expect that MEDNAX Inc will post 3.67 EPS for the current year.

In related news, insider John C. Pepia sold 3,500 shares of the business’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $48.18, for a total transaction of $168,630.00. Following the transaction, the insider now owns 30,148 shares in the company, valued at approximately $1,452,530.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is owned by insiders.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Tuesday, August 7th. ValuEngine raised shares of MEDNAX from a “strong sell” rating to a “sell” rating in a report on Friday, August 3rd. Credit Suisse Group raised shares of MEDNAX from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $47.00 to $55.00 in a report on Friday, August 3rd. Stifel Nicolaus set a $47.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research report on Thursday, August 2nd. Finally, Leerink Swann assumed coverage on shares of MEDNAX in a research report on Thursday, July 12th. They issued a “market perform” rating and a $50.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $54.71.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Further Reading: What is intrinsic value?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply